Research Article

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

Table 2

Retrospective studies included in meta-analyses.

Study, YearRegimenPTCL subgroup*nCR% OS

Kwong et al., 1997 [22]Anthracycline-basedNK/T nasal2466.7
Cheung et al., 1998 [2]Anthracycline-basedPTCL-NOS2469.62 yr 63%
NK/T nasal5156.02 yr 43%
Löpez-Guillermo et al., 1998 [23]Anthracycline-basedPTCL-combined17449.04 yr 38%
 PTCL-NOS9547.04 yr 32%
 ALCL3069.0
 AITL2237.0
 NK/T nasal1446.0
 ETTL1227.0
Pautier et al, 1999 [24]CHOP-likeAITL3360.65 yr 36%
Ribrag et al., 2001 [25]CHOP-type ± RTNK/T nasal728.6
Cheung et al., 2002 [26]CMTNK/T nasal6165.65 yr 41%
Kim et al., 2002 [27]CHOP ± RTPTCL-combined7852.65 yr 36%
 ALCL1369.2
 PTCL-NOS3151.6
 AITL540.0
 NK/T nasal2552.0
Reiser et al., 2002 [28]Anthracycline-basedPTCL-combined6662.05 yr 55%
 ALCL1979.0
 PTCL-NOS2860.7
 AITL728.6
Rüdiger et al., 2002 [29]Adriamycin-basedNon-ALCL PTCL965 yr 26%
Chim et al., 2004 [30]Anthracycline-based + RTNK/T nasal4765.9
Li et al., 2004 [31]CHOP-basedNK/T nasal local1850.05 yr 15%
CHOP-based + RTNK/T nasal local2774.15 yr 59%
CHOP-basedNK/T nasal syst1060.05 yr 30%
CHOP-based + RTNK/T nasal syst1030.05 yr 20%
Savage et al., 2004 [32]CHOP-typePTCL-NOS11764.15 yr 35%
 ALCL3355.05 yr 43%
 AITL1070.05 yr 36%
 NK/T nasal1773.05 yr 24%
 ETTL933.05 yr 22%
You et al., 2004 [33]CT + RTNK/T nasal165 yr 42%
CTNK/T nasal155 yr 20%
Escalón et al., 2005 [34]CHOPNon-ALCL PTCL2458.03 yr 43%
CHOP IntensiveNon-ALCL PTCL5259.03 yr 49%
Kim et al., 2005 [35]CHOP/COPBLAM-V + RTNK/T nasal1637.55 yr 59%
RTNK/T nasal3352.05 yr 76%
Sonnen et al., 2005 [36]CHOP-typePTCL-combined12553.05 yr 43%
 ALCL2171.05 yr 61%
 PTCL-NOS7055.05 yr 45%
 AITL3436.05 yr 28%
Li et al., 2006 [37]CHOP-based + RTNK/T nasal7184.55 yr 76%
CHOP-type aloneNK/T nasal333.3
Vose et al., 2008 [1]Anthracycline-basedPTCL-NOS3405 yr 32%
ALK Neg ALCL725 yr 49%
AITL2435 yr 32%
NK/T nasal1365 yr 42%
ETTL623 yr 20%

PTCL: peripheral T-cell lymphoma; n: number of patients; CR: complete response; OS: overall survival; ACVB: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; BACOP: Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone; Pred, prednisolone; COPBLAM: cyclophosphamide, vincristine, and prednisone with bleomycin, doxorubicin, and procarbazine; IMVP: ifosfamide, methotrexate, and etoposide; VACPE: vincristine, doxorubicin, cyclophosphamide, prednisone, and etoposide; NK/T nasal, NK/T-cell lymphoma nasal type; NOS: not otherwise specified; ALCL: anaplastic large cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; ETTL: enteropathy-type T-cell lymphoma; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; RT: radiation therapy; CMT: combined modality treatment; V: vincristine; syst, systemic; Neg: negative; CHOEP: cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone; CT: chemotherapy; CVAD: cyclophosphamide, doxorubicin, vincristine, and dexamethasone; VIP: vinblastine, ifosfamide, and cisplatin; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; EG: etoposide and gemcitabine; DI: dose-intensive; CEOP-B: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin; HDCT: high-dose chemotherapy; PBSCT: Peripheral blood stem cell transplant.
*PTCL-combined represents the whole group of PTCL patients. In cases where studies separated ALK-positive and ALK-negative ALCL and provided separate results for the two subgroups, ALK-positive patients were excluded from the meta-analysis. Non-ALCL PTCL indicates PTCL without any ALCL subtype included.